🇺🇸 Rimegepant/BHV3000 in United States

Rimegepant/BHV3000 (rimegepant-bhv3000) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Rimegepant/BHV3000 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in United States

Frequently asked questions

Is Rimegepant/BHV3000 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rimegepant/BHV3000 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Rimegepant/BHV3000 cost in United States?

annual_list: USD 79491.09 per year. Final patient cost depends on reimbursement and any patient access scheme.